NDATOPICALCREAM
Approved
Oct 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
DERMATOP E EMOLLIENT (prednicarbate) by Bausch + Lomb. Approved for psoriasis. First approved in 1993.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DERMATOP E EMOLLIENT is a topical corticosteroid cream containing prednicarbate, approved for the treatment of psoriasis. It is a small-molecule glucocorticoid that reduces inflammation and immune-mediated skin responses. The emollient formulation enhances skin penetration and provides moisturizing benefits alongside anti-inflammatory activity.
LOE Approaching
Product is approaching loss of exclusivity with minimal linked job activity, signaling a contracting brand team and declining commercial opportunity.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (1)
Career Relevance
DERMATOP E offers minimal career upside given its LOE-approaching status and zero linked job openings. Positions on this brand typically involve managing decline, supporting legacy customers, and transitioning to successor products or newer indications.
Brand Manager
Worked on DERMATOP E EMOLLIENT at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.